All In Biotech

Free tool

FAERS Monitor: Provocholine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019193 or its brand name (Provocholine, Methacholine Chloride). Reports on generic versions are filed under their own applications.

Reports

73

Serious

36

49% of reports

Hospitalization

14

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • chest discomfort8
  • dyspnoea7
  • fatigue7
  • headache6
  • dizziness5
  • drug ineffective5
  • urticaria5
  • angioedema4
  • anxiety4
  • asthma4
  • benign prostatic hyperplasia4
  • pain4
  • accidental exposure to product3
  • arthralgia3
  • back pain3

Reports by year received

View as table
YearReports
20041
20073
20081
20094
20102
20117
20123
20131
20153
20166
20173
20181
20197
20208
20213
20227
20234
20245
20252
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,086 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
benign prostatic hyperplasiaSignal4223.686.2677
angioedemaSignal426.110.073
chest discomfortSignal822.511.7144
asthmaSignal410.23.925
urticariaSignal58.63.727
accidental exposure to productSignal38.42.813
anxietySignal44.01.66
back pain33.71.24
dyspnoeaSignal73.61.811
dizzinessSignal52.91.25
headacheSignal62.81.35
fatigueSignal72.61.36
arthralgia32.10.71
pain41.90.71
drug ineffective51.10.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.